Study of the Drug Efalizumab (Raptiva), for Adult Patients With Moderate to Severe Plaque Psoriasis
Status:
Completed
Trial end date:
2011-04-06
Target enrollment:
Participant gender:
Summary
Our laboratory is studying a skin disease known as psoriasis. The purpose of this protocol is
to study the action and the effects of Efalizumab, on psoriasis. This medication has been
studied extensively and has been found to be effective and safe in the treatment of
psoriasis. The eligible patient will have 10% of his/her body surface area involved with
psoriasis vulgaris.